Cardiovascular Systems Inc Form 8-K November 14, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2016

Cardiovascular Systems, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware 000-52082 41-1698056
(State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.)
1225 Old Highway 8 Northwest
St. Paul, Minnesota 55112-6416
(Address of Principal Executive Offices and Zip Code)
(651) 259-1600
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

Effective November 11, 2016, Cardiovascular Systems, Inc. (the "Company") entered into a Distribution Agreement with Medikit Co., Ltd. to sell its Diamondback 360® Coronary and Peripheral Orbital Atherectomy Systems in Japan. On November 14, 2016, the Company issued a press release announcing the Distribution Agreement. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits

Exhibit Number Description

99.1 Press release dated November 14, 2016.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2016 CARDIOVASCULAR SYSTEMS, INC.

By: /s/ Laurence L. Betterley Laurence L. Betterley Chief Financial Officer

## EXHIBIT INDEX

Exhibit Number Description

99.1 Press release dated November 14, 2016.